SOLS Stock Analysis: Solstice Advanced Materials | NASDAQ
Specialty Chemicals | NASDAQ, USA | Market Cap: 8.897m USD | 12M Return: 27% | US83443Q1031 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 119M
Qual. Beats: 0
Rev. Trend: 100.0%
Warnings
Tailwinds
Seasonality 1.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Solstice Advanced Materials, Inc. (NASDAQ: SOLS) is a U.S.-headquartered specialty chemicals and advanced materials company that operates through two reporting segments. The Refrigerants & Applied Solutions (RAS) segment produces low global-warming-potential (LGWP) refrigerants, blowing agents, solvents, and aerosol materials under the Solstice, Genetron, and Aclar brands, serving applications such as pharmaceutical packaging and cleaning. The Electronic & Specialty Materials (ESM) segment supplies sputtering targets, high-strength fibers, and high-purity life science chemicals for semiconductor, defense, pharmaceutical, and construction end markets under the Spectra, Fluka, and Hydranal brands.
The company is classified within the GICS Materials sector and Commodity Chemicals sub-industry, was incorporated in 2025, and trades as a mid-cap common stock following its October 2025 IPO. Solstices product portfolio reflects a broader industry shift toward next-generation fluorochemicals and high-purity inputs, driven by regulatory phase-outs of legacy high-GWP refrigerants and rising demand from semiconductor and life science supply chains.
- AIM Act HFC phase-out accelerates LGWP refrigerant demand
- Semiconductor capex recovery lifts sputtering target sales
- EU F-Gas tightening expands Solstice refrigerant market opportunity
| Net Income: 210.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.03 > 0.02 and ΔFCF/TA -6.49 > 1.0 |
| NWC/Revenue: 19.73% < 20% (prev 15.68%; Δ 4.05% < -1%) |
| CFO/TA 0.10 > 3% & CFO 606.0m > Net Income 210.0m |
| Net Debt (1.77b) to EBITDA (891.0m): 1.99 < 3 |
| Current Ratio: 1.46 > 1.5 & < 3 |
| Outstanding Shares: last quarter (159.3m) vs 12m ago 0.37% < -2% |
| Gross Margin: 30.62% > 18% (prev 34.85%; Δ -4.23% > 0.5%) |
| Asset Turnover: 74.54% > 50% (prev 73.96%; Δ 0.57% > 0%) |
| Interest Coverage Ratio: 8.71 > 6 (EBIT TTM 671.0m / Interest Expense TTM 77.0m) |
| A: 0.14 (Total Current Assets 2.57b - Total Current Liabilities 1.76b) / Total Assets 5.92b |
| B: 0.04 (Retained Earnings 220.0m / Total Assets 5.92b) |
| C: 0.12 (EBIT TTM 671.0m / Avg Total Assets 5.49b) |
| D: 0.37 (Book Value of Equity 1.59b / Total Liabilities 4.33b) |
| Altman-Z'' = 2.22 = BBB |
| DSRI: 1.37 (Receivables 985.0m/659.0m, Revenue 4.09b/3.75b) |
| GMI: 1.14 (GM 34.85% / 30.62%) |
| AQI: 0.72 (AQ_t 0.21 / AQ_t-1 0.29) |
| SGI: 1.09 (Revenue 4.09b / 3.75b) |
| TATA: -0.07 (NI 210.0m - CFO 606.0m) / TA 5.92b) |
| Beneish M = -2.70 (Cap -4..+1) = A |
As of October 07, 2026, the stock is trading at USD 61.27 with a total of 2,599,801 shares traded. Over the past week, the price has changed by +9.39%, over one month by -5.05%, over three months by -9.84% and over the past year by +26.99%.
Current recommended Stop Loss: 58.50 (which is 4.5% or 1.3 ATR below the current price).
Solstice Advanced Materials has no consensus analysts rating.
P/E Trailing = 43.0846
P/E Forward = 17.0648
P/S = 2.1727
P/B = 5.8982
P/EG = 0.5095
Revenue TTM = 4.09b USD
EBIT TTM = 671.0m USD
EBITDA TTM = 891.0m USD
Long Term Debt = 1.98b USD (from longTermDebt, last quarter)
Short Term Debt = 350.0m USD (from shortTermDebt, last quarter)
Debt = 2.52b USD (from shortLongTermDebtTotal, last quarter) + Leases 109.0m
Net Debt = 1.77b USD (calculated: Debt 2.52b - CCE 750.0m)
Enterprise Value = 10.7b USD (8.90b + Debt 2.52b - CCE 750.0m)
Interest Coverage Ratio = 8.71 (Ebit TTM 671.0m / Interest Expense TTM 77.0m)
EV/FCF = 59.26x (Enterprise Value 10.7b / FCF TTM 180.0m)
FCF Yield = 1.69% (FCF TTM 180.0m / Enterprise Value 10.7b)
FCF Margin = 4.40% (FCF TTM 180.0m / Revenue TTM 4.09b)
Net Margin = 5.13% (Net Income TTM 210.0m / Revenue TTM 4.09b)
Gross Margin = 30.62% ((Revenue TTM 4.09b - Cost of Revenue TTM 2.84b) / Revenue TTM)
Gross Margin QoQ = 32.23% (prev 31.89%)
Tobins Q-Ratio = 1.80 (Enterprise Value 10.7b / Total Assets 5.92b)
Interest Expense / Debt = 3.06% (Interest Expense 77.0m / Debt 2.52b)
Taxrate = 23.86% (42.0m / 176.0m)
NOPAT = 510.9m (EBIT 671.0m * (1 - 23.86%))
Current Ratio = 1.46 (Total Current Assets 2.57b / Total Current Liabilities 1.76b)
Debt / Equity = 1.59 (Debt 2.52b / totalStockholderEquity, last quarter 1.59b)
Debt / EBITDA = 1.99 (Net Debt 1.77b / EBITDA 891.0m)
Debt / FCF = 9.83 (Net Debt 1.77b / FCF TTM 180.0m)
Total Stockholder Equity = 1.93b (last 4 quarters mean from totalStockholderEquity)
RoA = 3.82% (Net Income 210.0m / Total Assets 5.92b)
RoE = 10.89% (Net Income TTM 210.0m / Total Stockholder Equity 1.93b)
RoCE = 17.17% (EBIT 671.0m / Capital Employed (Equity 1.93b + L.T.Debt 1.98b))
RoIC = 11.87% (NOPAT 510.9m / Invested Capital 4.30b)
WACC = 7.00% (E(8.90b)/V(11.4b) * Re(8.33%) + D(2.52b)/V(11.4b) * Rd(3.06%) * (1-Tc(0.24)))
Discount Rate = 8.33% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 74.23 | Cagr: 0.18%
[DCF] Terminal Value 73.10% ; FCFF base≈301.2m ; Y1≈264.1m ; Y5≈213.4m
[DCF] Fair Price = 10.42 (EV 3.43b - Net Debt 1.77b = Equity 1.66b / Shares 158.8m; r=8.35% [WACC [floored]]; 5y FCF grow -15.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.24 | # QB: 0
Revenue Correlation: 99.98 | Revenue CAGR: 3.20% | SUE: N/A | # QB: 0
EPS current Quarter (2026-09-30): EPS=0.70 | Chg30d=-2.49% | Revisions=+67% | Analysts=7
EPS current Year (2026-12-31): EPS=2.88 | Chg30d=+0.17% | Revisions=+70% | GrowthEPS=+93.6% | GrowthRev=+7.4%
EPS next Year (2027-12-31): EPS=3.37 | Chg30d=+0.92% | Revisions=+70% | GrowthEPS=+17.0% | GrowthRev=+5.6%
[Analyst] Revisions Ratio: +87% (up=20, down=0)